A strain of Harbin Lactobacillus Schleifer JNDM with hypoglycemic function and its application
By discovering and using Lactobacillus Shriferi JNDM to promote islet cell proliferation and insulin secretion, the problem of the lack of effective blood sugar-lowering strain in the existing technology was solved, and the blood sugar-lowering strain in the human body was achieved. Effects and intestinal arrival ability, used for the treatment of diabetes.
Patent Information
- Application Number
- CN202410344743.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-25
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-03-25
AI Technical Summary
The prior art has not yet found a strain of Lactobacillus Shriver strain with the function of lowering blood sugar and assisting in the treatment of diabetes, and cannot effectively solve the treatment needs of diabetes.
Discovered and named as Lactobacillus Shrifer JNDM, this strain can survive in the human gastric juice environment and effectively reach the intestine by promoting the proliferation of pancreatic islet cells and insulin secretion, reducing blood sugar, and has higher acid and bile salt tolerance. , exert the function of lowering blood sugar.
Lactobacillus schliver JNDM significantly reduces blood sugar and is used to prepare blood sugar-lowering drugs or functional products for preventing, treating or assisting in the treatment of type 2 diabetes and its complications. It has high adhesion and long-term blood sugar-lowering effects.
Smart Images

Figure CN118421501B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of microorganisms, and in particular to a strain of Harbin lactobacillus with blood sugar lowering function and application thereof. Background Art
[0002] Diabetes is a common endocrine and metabolic disorder characterized by persistent hyperglycemia. Typical diabetic patients show symptoms of polydipsia, polyuria, polyphagia, and weight loss. Clinically, diabetes is divided into two categories: Type I diabetes is an autoimmune disease with an absolute lack of insulin secretion. In addition to controlling diet, long-term insulin injections are required for the treatment of this type of disease; Type II diabetes is caused by relatively insufficient insulin secretion or insulin resistance, accounting for more than 90% of the number of diabetic patients. Long-term high blood sugar can damage body organs and cause chronic complications such as diabetic nephropathy, retinopathy, and peripheral neuropathy. It seriously threatens human life and health and imposes a huge economic burden on society and patients.
[0003] The number of people suffering from diabetes in China is increasing year by year, and it is expected to reach 10% of the total population in China in 2030. With the improvement of people's living conditions and the arrival of social aging, coupled with the gradual increase in chronic patients such as diabetes, cardiovascular disease, liver and kidney disease, people's awareness of health is gradually increasing, and the demand for the diagnosis and treatment of diabetes is gradually expanding. There is no effective cure for diabetes, and it needs to be supplemented by drug treatment and diet control. Related prior art studies have shown that the occurrence and development of diabetes is closely related to the disorder of human intestinal flora, impaired intestinal mucosal barrier function, and the activation of low-grade inflammatory response caused by it. Therefore, there are many research and development of microbial strains for diabetes, aiming to discover new microorganisms that can treat diabetes. For example, the Chinese invention patent with publication number CN115948273A discloses Bifidobacterium bifidum for the treatment of diabetes and related diseases, and finds that Bifidobacterium bifidum ibiome001 is a potential functional strain for the treatment of metabolic syndromes such as obesity and diabetes; the Chinese invention patent with publication number CN114533768A discloses the use of a probiotic strain of Lactobacillus in the preparation of a diabetes treatment drug, and finds that a Lactobacillus can treat diabetes. Therefore, the discovery of probiotic strains with clear blood sugar-lowering functions and their related products has huge market application prospects.
[0004] Harbin Lactobacillus Schleifer is widely present in traditional Chinese fermented vegetables. It is safe to eat and can be used to ferment kimchi, sauerkraut, etc. It has good acid production and flavor production effects, but the existing technology has not yet reported its blood sugar lowering and auxiliary treatment of diabetes function. Summary of the invention
[0005] The purpose of the present invention is to solve the above technical problems and provide a strain of Harbin Lactobacillus Schleifer JNDM, which can lower blood sugar and assist in the treatment of diabetes; another purpose of the present invention is to provide its application.
[0006] To achieve the above object, the present invention adopts the following technical solutions:
[0007] The present invention accidentally discovered a strain of Harbin Schleiferilactobacillus harbinensis that can lower blood sugar function by promoting pancreatic islet cell proliferation and insulin secretion, named JNDM. The Harbin Schleiferilactobacillus JNDM was deposited in the Guangdong Provincial Microbiological Culture Collection Center GDMCC on December 11, 2023. The storage address is: 5th Floor, Laboratory Building, No. 100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province; the storage number is: GDMCCNo.64143.
[0008] The physiological and biochemical properties of the strain are as follows: Harbin Lactobacillus Schleifer JNDM is a Gram-positive bacterium, belonging to the genus Lactobacillus Schleifer, with a rod-shaped body, anaerobic or facultative anaerobic; the colony is a milky white round protrusion, the surface is moist and smooth, opaque, and has a fermented acid aroma. Its 16S rDNA length is 1476bp, and the sequence is shown in SEQ ID NO.1. This strain can grow on MRS medium, with an optimal growth temperature of 37°C and an optimal growth pH of 5.0-6.0. The anaerobic growth test of Harbin Lactobacillus Schleifer JNDM is positive, the catalase test is negative, the indole test is negative, the glucose fermentation test is positive, the nitrate reduction test is negative, the raffinose fermentation test is positive, the sucrose fermentation test is positive, the mannitol fermentation test is negative, the sorbitol fermentation test is negative, the glycerol fermentation test is negative, and the gas production test is negative.
[0009] Since the Harbin Lactobacillus Schleifer of the present invention has the function of promoting the proliferation of pancreatic islet cells and insulin secretion to lower blood sugar, the present invention claims the following scheme:
[0010] The present invention seeks to protect the use of the above-mentioned Harbin Lactobacillus Schleifer JNDM in the preparation of medicines or functional products for preventing, treating or assisting in the treatment of type 2 diabetes or its complications.
[0011] The present invention seeks to protect the use of the above-mentioned Harbin Lactobacillus Schleifer JNDM in the preparation of hypoglycemic drugs or products with hypoglycemic function.
[0012] Furthermore, the Harbin Lactobacillus Schleifer JNDM achieves blood sugar reduction by promoting pancreatic islet cell proliferation and insulin secretion.
[0013] The present invention claims a hypoglycemic drug, comprising the above-mentioned Harbin Lactobacillus Schleifer JNDM and / or its bacterial liquid.
[0014] Furthermore, the above-mentioned hypoglycemic drug also includes necessary pharmaceutical excipients or carriers.
[0015] Furthermore, the above-mentioned hypoglycemic drug is in the form of tablets, capsules, lyophilized powder or oral preparation.
[0016] The present invention seeks to protect a product with hypoglycemic function, comprising the above-mentioned Harbin Lactobacillus Schleifer JNDM.
[0017] The present invention claims a blood sugar lowering bacterial powder, comprising the above-mentioned Harbin Lactobacillus Schleifer JNDM and / or its metabolites.
[0018] Preferably, the metabolite is the intracellular centrifugal precipitate or supernatant or the fermentation product after separating the bacterial cells.
[0019] Furthermore, the viable count of Harbin Lactobacillus Schleifer JNDM in the hypoglycemic bacterial powder is 5×10 8 -1×10 12 CFU / g.
[0020] The beneficial effects of the present invention are as follows:
[0021] (1) The present invention discovered a strain of Schleiferilactobacillus harbinensis that can lower blood sugar function by promoting pancreatic islet cell proliferation and insulin secretion, named JNDM. The Harbin Schleiferilactobacillus JNDM was deposited in the Guangdong Provincial Microbiological Culture Collection Center GDMCC on December 11, 2023, with the preservation number: GDMCC No.64143.
[0022] (2) The Harbin Lactobacillus Schiffli JNDM has higher acid resistance and bile salt tolerance, and can have a higher survival rate in the human gastric juice environment, which can ensure that more active probiotics can smoothly reach the intestines and play a role. It also has a high adhesion property and can promote the proliferation of pancreatic islet cells and insulin secretion to lower blood sugar function for a long time.
[0023] (3) Based on the hypoglycemic effect of this strain, it can be used to prepare hypoglycemic drugs or hypoglycemic functional products, and thereby prevent, treat or assist in the treatment of type 2 diabetes or its complications. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 The phylogenetic tree is constructed by homology comparison of 16s rDNA sequences of Harbin Lactobacillus schleifer JNDM and related strains of the present invention.
[0025] Figure 2 It is the colony morphology picture and microscopic morphology picture of Harbin Lactobacillus Schleifer JNDM of the present invention.
[0026] Figure 3 The figure is the growth curve of Harbin Lactobacillus Schleifer JNDM of the present invention and the commercially available Harbin Lactobacillus Schleifer.
[0027] Figure 4 This is a graph showing the pancreatic islet cell survival rate in Example 5 of the present invention.
[0028] Figure 5 This is a graph of insulin content in Example 5 of the present invention.
[0029] Figure 6 This is a graph showing the expression levels of cellular inflammatory factors in Example 5 of the present invention.
[0030] Figure 7 The graph shows the changes in fasting blood glucose of mice in each week.
[0031] Figure 8 Bar graph showing the mean glycated hemoglobin in mice.
[0032] Fig. 9 Graph of average insulin levels in mice.
[0033] Fig.10 Mouse pancreatic islet tissue section. DETAILED DESCRIPTION
[0034] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.
[0035] Unless otherwise specified, the biological drugs, reagents, and biological samples involved in the present invention are all commercially available, and their use meets the conventional requirements of those skilled in the art.
[0036] Example 1 Isolation and screening of Harbin Lactobacillus Schleifer JNDM strain
[0037] 1. Experimental Methods
[0038] (1) Culture medium preparation
[0039] MRS liquid culture medium: tryptone 10g; yeast powder 5g; beef extract 10g; glucose 20g; diamine hydrogen citrate 2g; sodium acetate 5g; K2HPO4·3H2O 2.6g; MgSO4·7H2O 0.2g; MnSO4·4H2O 0.05g; Tween 80 1mL. Adjust pH to 6.8±0.2; make up to 1L, and sterilize at 121℃ for 15min.
[0040] MRS solid culture medium: before sterilization, add agar to the above liquid culture medium so that its mass volume concentration in the liquid culture medium is 20g / L.
[0041] (2) Strain isolation and screening
[0042] a. Take 1 g of the fermented kimchi sample, inoculate it into 200 mL of MRS liquid culture medium under sterile conditions, and culture it in an anaerobic incubator at 37°C for 48 h.
[0043] b. The mixed bacterial liquid after culture is graded diluted and spread on MRS solid culture medium, placed in an anaerobic incubator at 37°C for 24 hours, and when there are obvious colony growth, single bacteria are picked and streaked on MRS solid culture medium for isolation and culture, with the culture conditions being consistent.
[0044] c. When obvious colonies grow on the streaked plate, pick a single bacterium and inoculate it into MRS liquid culture medium. After incubation at 37°C in an anaerobic incubator for 48 hours, collect the bacteria by centrifugation and extract the bacterial DNA for strain identification.
[0045] (3) Identification of bacterial species
[0046] Identification method: 16S rDNA sequencing, the specific operation is: collect the cultured bacterial cells, use the DNA extraction kit (purchased from Nanjing Novozyme Biotechnology Co., Ltd.) to extract DNA, perform PCR amplification after extraction, and finally send it to Shanghai Biotechnology for sequencing analysis. The PCR primers are universal primers: P0 (27F), P6 (1492R), the amplification system is shown in Table 1, and the amplification steps and parameter conditions are shown in Table 2.
[0047] Table 1 16S sequencing PCR amplification system
[0048] Reagents 25μL reaction system Taq enzyme 12.5μL Upstream primer (p0) 1μL Downstream primer (p6) 1μL DNA 1μL <![CDATA[ddH2O]]> Make up to 25 μL with water
[0049] Table 2 16S sequencing PCR amplification steps and parameter conditions
[0050]
[0051]
[0052] 2. Experimental results
[0053] The isolated colonies are opaque white colonies that can be cultured anaerobically in MRS medium. PCR amplification was performed using universal primers for PCR amplification of the 16S rRNA gene as primers to obtain an amplified band of 1476 bp in length. The 16S sequencing sequence is shown in SEQ ID NO.1. The measured 16S rDNA sequence was compared and analyzed with the GenBank database using BLAST software. The nucleotide homology was compared with the registered sequences in Genebank using the Blast program to construct a phylogenetic tree as shown in Figure 1 As shown by Figure 1 It can be seen that the 16SrDNA sequence of this bacterium is 99.50% homologous to Schleiferilactobacillus harbinensis. Therefore, the strain is confirmed to be Schleiferilactobacillus, Harbin Schleiferilactobacillus (Schleiferilactobacillus harbinensis), named JNDM, and deposited in Guangdong Provincial Microbiological Culture Collection Center GDMCC on December 11, 2023, with a deposit number of GDMCC No. 64143, and a deposit address of 5th Floor, Compound Experimental Building (Building 59), No. 100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province.
[0054] Example 2 Morphological and physiological and biochemical identification of bacterial strains
[0055] 1. Experimental Methods
[0056] The identified Harbin Schiffli Lactobacillus JNDM was inoculated on an MRS plate for 2 days to observe the size and morphology of the colonies; at the same time, the morphology of the individual bacteria was observed under a microscope. Harbin Schiffli Lactobacillus JNDM was inoculated into a liquid culture medium, and the optical density value (OD 600 ), detect the aerobic characteristics of the strain, the temperature suitable for growth and other biochemical characteristics, the above method is mainly based on the "Common Bacteria System Identification Manual" (Dong Xiuzhu, Cai Miaoying. 2001. Common Bacteria System Identification Manual. Beijing: Science Press)
[0057] 2. Experimental results
[0058] The colonies and microscopic morphology of Harbin Lactobacillus schfreii JNDM are as follows Figure 2 As shown by Figure 2It can be seen that the Harbin Schleifer Lactobacillus JNDM is rod-shaped or rod-shaped, the colony morphology is milky white, the colony shape is milky white round protrusions, the colony size is 0.5-2.0mm, the surface is moist and smooth, opaque, and has a fermented sour aroma. The Harbin Schleifer Lactobacillus JNDM can be cultured anaerobically in MRS medium, and the bacteria are rod-shaped under the microscope, anaerobic or facultative anaerobic; this strain can grow on MRS medium, the optimal growth temperature is 37°C, and the optimal growth pH is 5.0-6.0. The Harbin Schleifer Lactobacillus JNDM anaerobic growth test is positive, the catalase test is negative, the indole test is negative, the glucose fermentation test is positive, the nitrate reduction test is negative, the raffinose fermentation test is positive, the sucrose fermentation test is positive, the mannitol fermentation test is negative, the sorbitol fermentation test is negative, the glycerol fermentation test is negative, and the gas production test is negative. Overall, it is similar to the characteristics of Harbin Schleifer Lactobacillus.
[0059] Example 3 Strain growth and acid production and gastric acid resistance determination
[0060] 1. Experimental Methods
[0061] (1) Compare the strain growth and acid production performance of Harbin Lactobacillus schiffrey JNDM of the present invention and the commercially available strain of the same species. The specific experimental method is as follows: The strain Harbin Lactobacillus schiffrey JNDM of the present invention and the commercially available Harbin Lactobacillus schiffrey (purchased from Ningbo Mingzhou Biotechnology Co., Ltd.) are inoculated in 250 mL MRS medium under sterile conditions at an inoculation rate of 3% and cultured for 24 hours for activation. After activation, they are re-inoculated in MRS medium and cultured anaerobically at 37°C. Samples are taken every 3 hours to measure the OD value at 600 nm to draw a growth curve. Samples are taken at 8 hours, 16 hours, and 24 hours to measure the number of viable bacteria and total acid. Method for determining the number of viable bacteria: plate coating method; method for determining the total acid: acid-base titration method.
[0062] (2) The acid resistance of the strain Harbin Lactobacillus schfreii JNDM of the present invention was compared with that of a commercially available strain of the same species to characterize its ability to survive the acidic environment of the human gastrointestinal tract. The specific experimental method is as follows:
[0063] a. Preparation of artificial gastric juice: Dissolve pepsin in 0.2% sodium chloride solution to a final concentration of 0.3 g / L, and adjust the pH to 3.0 with hydrochloric acid.
[0064] b. The activated strain of the present invention, Harbin Lactobacillus Schiffrey JNDM and commercially available Harbin Lactobacillus Schiffrey were inoculated in MRS culture medium and cultured for 24h, 2mL bacterial solution was centrifuged at 5000r / min for 3min, the supernatant was removed, the bacterial body was washed twice with sterile physiological saline, the bacterial body was collected by centrifugation in the same way, resuspended in 10mL artificial gastric juice, placed in 37°C, incubated in a shaking table at 100r / min, and the viable count was detected at 0h and 3h, respectively, and the survival rate was calculated. The survival rate was calculated with reference to the following formula: survival rate (%) = (N3 / N0) × 100%, wherein N3 represents the viable count of 3h; N0 represents the initial viable count.
[0065] 2. Experimental results
[0066] (1) Strain growth curve Figure 3 As shown by Figure 3 It can be seen that the growth rate of this bacterium JNDM in MRS medium is lower than that of the commercially available Harbin Schiffli Lactobacillus in the early stage (9h), and the growth rate accelerates in the later stage (after 9h) and is higher than that of the commercially available Harbin Schiffli Lactobacillus.
[0067] The results of the strain acid production performance test are shown in Table 3. It can be seen from Table 3 that the strain Harbin Schiffli Lactobacillus JNDM has a higher acid resistance than the commercially available Harbin Schiffli Lactobacillus, and can have a higher survival rate in the acidic environment of human gastric juice. This property can indicate that the strain JNDM has a smaller impact on the decrease in the number of live bacteria during oral delivery than the general Harbin Schiffli Lactobacillus gastric acid environment, which can ensure that more active probiotics can smoothly reach the intestines and play a role.
[0068] Table 3 Acid production and viable count of Harbin Lactobacillus scheffleri JNDM and commercially available Harbin Lactobacillus scheffleri
[0069]
[0070] (2) The results of gastric acid resistance test are shown in Table 4. It can be seen from Table 4 that the 3-hour survival rate of Harbin Lactobacillus scheffleri JNDM of the present invention under simulated human gastric acid conditions is 95.62%, which is 1.92 times that of commercially available Harbin Lactobacillus scheffleri, indicating that Harbin Lactobacillus scheffleri JNDM of the present invention can maintain a higher survival rate in the acidic environment of the human stomach.
[0071] Table 4 Survival of Harbin Lactobacillus scheffleri JNDM and commercially available Harbin Lactobacillus scheffleri in gastric acid
[0072]
[0073] Example 4 Bile salt tolerance and intestinal adhesion ability of strains
[0074] 1. Experimental Methods
[0075] (1) Determination of the bile tolerance of strains
[0076] The growth of Harbin Lactobacillus Schiffrey JNDM of the present invention and commercially available Harbin Lactobacillus Schiffrey under different bile salt concentrations was determined to characterize the tolerance of Harbin Lactobacillus Schiffrey JNDM under different bile salt concentrations. The determination method is as follows: Bile salts (specifically, Solebow pig bile salts (bile acid content is 65%)) are added to the MRS culture medium to make the bile salt concentration (w / v) 0, 0.1%, 0.3%, 0.5%, 0.7%, respectively, and the activated Harbin Lactobacillus Schiffrey JNDM of the present invention and commercially available Harbin Lactobacillus Schiffrey are inoculated into the MRS culture medium at an inoculum size of 3%, and cultured anaerobically at 37°C for 24h, and the OD value is detected at 600nm. The bile salt tolerance (ABILITY BILESALTS, ABS) is used as an evaluation index of the bile salt tolerance of lactic acid bacteria, and the bile salt tolerance is expressed by the following formula:
[0077]
[0078] Where: A BS is the bile salt tolerance, μ mBS μ is the OD600 value of lactic acid bacteria cultured in medium with different bile salt concentrations for 24 h; m It is the OD600 value of lactic acid bacteria after 24 hours of culture without bile salts.
[0079] (2) Determination of strain intestinal adhesion ability
[0080] A. strain hydrophobicity determination: Harbin Lactobacillus schiffii JNDM of the present invention after activation and commercially available Harbin Lactobacillus schiffii were inoculated in MRS culture medium and cultivated for 24h, 2mL bacterial solution was centrifuged for 3min at 5000r / min, and supernatant was removed. The thalline was washed twice with sterile PBS buffer, and the thalline was centrifuged and collected in the same manner. With PBS buffer as a contrast, the thalline was reselected with PBS to OD600nm to about 0.8, which was designated as A0. 1mL of dimethylbenzene was added to the 3mL bacterial suspension, fully mixed, and left standstill for 30min at room temperature, and aqueous phase was separated from the organic phase, and aqueous phase was taken, and OD value was detected at 600nm, which was designated as A1. The hydrophobicity of the thalline was calculated according to the following formula: thalline hydrophobicity (%) = [(A0-A1) / A0] × 100%.
[0081] b. Determination of the self-aggregation of strains: The activated Harbin Lactobacillus Schiffli JNDM of the present invention and the commercially available Harbin Lactobacillus Schiffli were inoculated in MRS medium and cultured for 24 hours, 2 mL of bacterial solution was centrifuged at 5000 r / min for 3 minutes, the supernatant was removed, the bacteria were washed twice with sterile PBS buffer, and the bacteria were collected by centrifugation in the same way. Using PBS buffer as a control, the bacteria were re-selected with PBS to an OD600nm of about 0.8, which was recorded as A0. Take 1 mL of the lactic acid bacteria suspension after adjusting the concentration, mix well, and incubate at room temperature for 5 hours. Take the surface bacterial solution (no blowing, suction, or vibration), and measure the OD value at 600nm, which is recorded as A1. The self-aggregation of the bacteria is calculated according to the following formula: Self-aggregation of bacteria (%) = (1-A1 / A0) × 100%.
[0082] c. In vitro adhesion ability of Caco-2 cells
[0083] Construction of in vitro adhesion model: Commercially purchased Caco-2 cells were cultured in DMEM high-glucose medium containing 10% fetal bovine serum at 37°C and 5% CO2. When the cells were confluent to about 80%, they were passaged at a concentration of 500,000 cells / mL in a 6-well plate. The medium was changed every 2 days until they were fully differentiated. The culture time was about 15 days, at which time the in vitro adhesion model was successfully established.
[0084] Adhesion assay: Harbin Lactobacillus scheffleri JNDM of the present invention and commercially available Harbin Lactobacillus scheffleri bacterial suspension resuspended in DMEM medium were added to the differentiated Caco-2 in vitro adhesion model, and the number of viable bacteria was adjusted to 1×10 7 CFU / mL, recorded as N0, placed in a cell culture environment for incubation for 2 hours, remove the supernatant, wash twice with sterile PBS, digest the cells and bacteria with trypsin, collect and count the live bacteria, recorded as N1. The adhesion rate is calculated according to the following formula: adhesion rate (%) = (N1 / N0) × 100%.
[0085] 2. Experimental results
[0086] (1) The survival of the Harbin Schiffrey Lactobacillus JNDM of the present invention and the commercially available Harbin Schiffrey Lactobacillus under bile salt concentrations is shown in Table 5. It can be seen from Table 5 that as the bile salt concentration increases, the bile salt tolerance of Harbin Schiffrey Lactobacillus JNDM and the commercially available Harbin Schiffrey Lactobacillus decreases, but the bile salt tolerance of Harbin Schiffrey Lactobacillus JNDM at the same concentration is significantly higher than that of the commercially available Harbin Schiffrey Lactobacillus.
[0087] Table 5 Harbin Lactobacillus Schiffrey JNDM and commercially available Harbin Lactobacillus Schiffrey ABS assay results
[0088]
[0089]
[0090] (2) The adhesion properties of the Harbin Lactobacillus schfreii JNDM of the present invention and the commercially available Harbin Lactobacillus schfreii are shown in Table 6. It can be seen from Table 6 that the hydrophobicity of the Harbin Lactobacillus schfreii JNDM of the present invention is higher than that of the commercially available Harbin Lactobacillus schfreii, and its self-aggregation force and adhesion rate are much higher than those of the commercially available Harbin Lactobacillus schfreii, indicating that the adhesion property of Harbin Lactobacillus schfreii JNDM is better.
[0091] Table 6 Adhesion properties of Harbin Lactobacillus schfreundii JNDM and commercially available Harbin Lactobacillus schfreundii
[0092] Adhesion properties Harbin Lactobacillus Schiffley JNDM Lactobacillus schiffii Hydrophobicity 95.7±1.8% 83.2±2.1% Self-cohesion 67.3±5.4% 36.5±4.4% Adhesion rate 56.8±7.4% 21.4±4.7%
[0093] Example 5 Effect of Harbin Lactobacillus schfreii JNDM on pancreatic islet cell proliferation and insulin secretion
[0094] 1. Experimental Methods
[0095] Sample preparation: The activated Lactobacillus scheffleri JNDM of the present invention and the commercially available Lactobacillus scheffleri of Harbin were inoculated in MRS medium and cultured for 24 hours, 2 mL of bacterial solution was centrifuged at 10000 r / min for 5 minutes, the supernatant and the bacteria were collected, the bacteria were washed twice with sterile PBS buffer and resuspended, and the cells were crushed by ultrasonic cell disruptor, centrifuged at 10000 r / min for 5 minutes, and the supernatant was collected to obtain the bacterial content. RIN-m5F is a clone of rat islet cell RIN-m, which can secrete higher insulin and was purchased from Wuhan Punosai Life Science Technology Co., Ltd.
[0096] (1) Establishment of pancreatic islet cell injury model
[0097] RIN-m5f cells in the logarithmic growth phase and in good growth condition were digested with 0.25% (v / v) trypsin and made into a single cell suspension by pipetting. 5 The cells were inoculated at a density of 100 / mL in a 96-well plate and cultured for 24 hours. The normal group remained unchanged, and the insulin injury model group was added with a medium containing 33.3 mM glucose and 0.2 mM palmitic acid (high-sugar and high-fat medium). After further culture for 24 hours, the medium was changed and the medication was given according to the following groups in Table 7:
[0098] Table 7 Islet cell administration and culture grouping
[0099]
[0100]
[0101] After administration, the cells were cultured for 24 h, and the cell survival rate, insulin secretion and inflammatory factor expression in each group were detected according to the following methods.
[0102] (1) Cell viability detection: CCK8 method
[0103] RIN-m5F cell suspension (100 μL / well) was inoculated in a 96-well plate at a cell density of 2×10 4 / well, put into cell culture incubator, culture for 24h; after the cells adhere to the wall, discard the old culture medium, add the corresponding fermentation liquid prepared by Harbin Lactobacillus schiffli JNDM and commercially purchased Harbin Lactobacillus schiffli to each well as intervention according to the experimental design, continue to culture for 24h, and set 6 duplicate wells and corresponding control groups in each group; discard the old culture medium, add 90μL serum-free culture medium and 10μL CCK-8 solution to each well, put into incubator, incubate for 4h in dark, and the culture liquid can be observed to change from pink to yellow by naked eyes; use multifunctional microplate reader to measure the OD value of each well at 450nm wavelength;
[0104] The cell survival rate was calculated as follows: cell survival rate = [(OD value of experimental well - OD value of blank well) / (OD value of control well - OD value of blank well)] × 100%.
[0105] (2) Insulin content detection
[0106] RIN-m5f cells were cultured at a cell number of 1.0 × 10 5 The cells were inoculated into a 24-well plate, and drugs were added according to the groups after the cells adhered to the wall. The culture was continued for 48 hours, the culture medium was discarded, and normal culture medium was used for another 24 hours to collect the supernatant, and the insulin content was determined using an ELISA kit.
[0107] (3) Detection of inflammatory factors in islet cells RIN-m5F:
[0108] a. RNA extraction
[0109] RIN-m5F cells were inoculated in 6-well plates, cultured according to experimental groups and intervened for 24 hours, then the culture medium was discarded and washed with PBS three times, 3 minutes each time. Then 1 mL of Trizol lysis solution was added, and the cells in each well were scraped off with a scraper. The cells were left to stand at room temperature for 5 minutes for cell lysis, and the lysate was transferred to a clean 1.5 mL EP tube and vortexed to shake well. 0.2 mL of chloroform was added to each 1 mL of Trizol lysis solution, and the mixture was mixed vigorously and left to stand at room temperature for 3 minutes. The centrifuge was set to 4°C in advance, centrifuged at 12000 rpm for 15 minutes, and the upper clear aqueous phase was carefully taken to a new enzyme-free EP tube and placed on ice; an equal volume of isopropanol was added to each tube, and after gently shaking and mixing, it was left to stand on ice for 10 to 15 minutes; the centrifuge was set to 4°C and centrifuged at 12000 rpm for 10 minutes. At the same time, 75% ethanol diluted with DEPC water was prepared on ice; after centrifugation, the supernatant was removed, and the white precipitate at the bottom of the tube was the extracted RNA. Add 75% ethanol, use a pipette to gently blow the precipitate, including the residue on the tube wall, and mix thoroughly to dissolve the RNA. Set the centrifuge to 4°C, 12000rpm for 5-10 minutes, discard the supernatant, open the EP tube and dry the precipitate for about 5-10 minutes; add an appropriate amount of DEPC water to blow and dissolve the RNA, and mix it thoroughly; use NanoDrop photometer to measure the RNA concentration, so that the concentration is between 0.5 and 1.0μg / μL. If the concentration is too high, add an appropriate amount of DEPC water to dilute it; to ensure the purity of RNA, OD260 / OD280 should be between 1.9 and 2.1; each sample is tested 3 times, and the RNA is immediately reverse transcribed or stored in a -80°C refrigerator for subsequent experiments.
[0110] b. cDNA preparation
[0111] The extracted RNA was prepared into a reverse transcription reaction system according to Table 8, and reverse transcription was performed according to the procedure in Table 9.
[0112] Table 8 Reverse transcription reaction system (50 μL)
[0113] Composition Stock concentration Volume μL 10×PCR Buffer 15mM 5 <![CDATA[MgCl2]]> 25mM 15 dNTP Mix 25mM 1 M-MLV Reverse Transcriptase 200 U / μL 0.625 RNase Inhibitor 20 U / μL 0.5 Random Primer 100μM 1 <![CDATA[RNase-free H2O]]> 21.875 RNA 40ng / μL 5
[0114] Table 9 Reverse transcription reaction procedure
[0115] Temperature / ℃ Time / min 25 10 48 40 95 5 4 ∞
[0116] c. Fluorescence quantitative PCR step: refer to the cDNA sequence of the target gene in GeneBank, use Primer Premier software to design the corresponding primers, after Blast comparison verification, the primer sequence is synthesized by Shanghai Shenggong Biotechnology Co., Ltd., with β-actin as the internal reference. The detailed primer and amplification related information are as follows: the required primer sequences are shown in SEQ ID NO.2-13 in Table 10, the amplification system is shown in Table 11, and the amplification program is shown in Table 12. After amplification, the relative expression of the mRNA of the target gene of fluorescence quantitative PCR is 2 -ΔΔCt Calculated by the method, where △Ct = Ct value of target gene - Ct value of reference gene, △△Ct = △Ct of experimental group - △Ct of control group, 2 -ΔΔCt It indicates the fold change of the expression of the target gene in the experimental group relative to that in the control group.
[0117] Table 10 Fluorescence quantitative PCR primer sequences
[0118]
[0119]
[0120] Table 11 Fluorescence quantitative PCR amplification system
[0121] Reagents 17μL reaction system 2×SYBR Green Mix 8.5μL Forward primer (5 μM) 0.425μL Reverse primer (5 μM) 0.425μL RNase-free HO 6.4μL cDNA 1.25μL
[0122] Table 12 Fluorescence quantitative PCR amplification program
[0123] 95℃ 10min 95℃ 15s (40 cycles) 60℃ 1min (40 cycles) Melting curve PCR Amplifier
[0124] 2. Experimental results
[0125] (1) Islet cell survival rate results Figure 4 As shown by Figure 4 It can be seen that compared with the commercially available Harbin Schiffli Lactobacillus, the Harbin Schiffli Lactobacillus JNDM of the present invention, its contents (dosing group 1) and supernatant (dosing group 2) can significantly promote the survival and proliferation of pancreatic islet cells, and are significantly higher than the commercially available Harbin Schiffli Lactobacillus. The commercially available Harbin Schiffli Lactobacillus, its contents (dosing group 3) and supernatant (dosing group 4) have no promoting effect.
[0126] (2) The results of insulin content test are as follows Figure 5 As shown by Figure 5It can be seen that compared with the commercially purchased Harbin Schfrei Lactobacillus, the Harbin Schfrei Lactobacillus JNDM of the present invention, its contents (dosing group 1) and supernatant (dosing group 2) can significantly promote the secretion of insulin in pancreatic cells, and are significantly higher than the commercially purchased Harbin Schfrei Lactobacillus. The commercially purchased Harbin Schfrei Lactobacillus, its contents (dosing group 3) and supernatant (dosing group 4) have no effect on promoting the secretion of insulin in pancreatic cells.
[0127] (3) The results of islet cell RIN-m5F inflammatory factor detection are as follows Figure 6 As shown by Figure 6 It can be seen that compared with the commercially purchased Harbin Schiffli Lactobacillus, the Harbin Schiffli Lactobacillus JNDM of the present invention, its contents (dosing group 1) and supernatant (dosing group 2) can significantly inhibit the expression of various inflammatory factors such as TNF-α, IL-6, IL-1β and MCP-1, and are significantly higher than the commercially purchased Harbin Schiffli Lactobacillus. The commercially purchased Harbin Schiffli Lactobacillus, its contents (dosing group 3) and supernatant (dosing group 4) have no inhibitory effect on the expression of inflammatory factors in pancreatic islet cells.
[0128] Therefore, compared with the commercially available Harbin Lactobacillus schfreundii, the Harbin Lactobacillus schfreundii JNDM of the present invention can significantly promote the proliferation and survival of pancreatic islet cells, insulin secretion, and significantly inhibit the expression of cellular inflammatory factors.
[0129] Example 6 Animal Experiment on Treatment of Type II Diabetes
[0130] 1. Experimental Grouping
[0131] Normal mice: db / m mice, 6 weeks old male, 6 mice. Diabetic mice: db / db mice, 6 weeks old male, 54 mice. db / db mice carry a mutation in the Leptin gene, thus showing symptoms of type 2 diabetes. db / db (C57BL / KsJ) mice have a point mutation in the Leptin receptor, which leads to a disorder in the leptin signaling pathway, resulting in obesity, insulin resistance, hyperglycemia, fatty liver and other symptoms in mice. Obvious obesity and increased fasting blood sugar, increased water intake and urine output can occur in mice 6 weeks after birth, which is most obvious at 8-12 weeks, and complications such as diabetic nephropathy may occur. db / db mice are usually used as the control group of the experiment with db / m mice. The mice were randomly divided into 9 groups, with 6 mice in each group, divided into normal group, model group, control group, drug administration group 1-3; drug administration group 4-6, and the grouping and drug administration relationship are shown in Table 13.
[0132] Table 13 Grouping and administration of mice
[0133] Grouping Handling medications Normal group Normal saline Model Group Normal saline Control group Metformin Treatment group 1 <![CDATA[High-dose Lactobacillus helveticus JNDM from Harbin (dose: 1×10 9 CFU / animal / day)]]> Treatment group 2 <![CDATA[Low-dose Lactobacillus helveticus JNDM from Harbin (dose: 1×10 8 CFU / animal / day)]]> Treatment group 3 Harbin Schiffley Lactobacillus JNDM deactivated bacterial culture solution (dosage: 10mL / kg / day) Treatment group 4 <![CDATA[High-dose commercially available Lactobacillus rhamnosus strain from Harbin (dose: 1×10 9 CFU / animal / day)]]> Treatment group 5 <![CDATA[Low-dose commercially available Lactobacillus paracasei Shirota (dose: 1×10 8 CFU / animal / day)]]> Treatment group 6 Commercially purchased culture solution of deactivated Lactobacillus schiffii from Harbin (dosage: 10 mL / kg / day)
[0134] Note: The culture broth of the deactivated Lactobacillus scheffleri JNDM and the culture broth of the commercially purchased deactivated Lactobacillus scheffleri in Table 13 are prepared by inoculating the strain at a 3% inoculum into 250 mL of MRS medium under sterile conditions and culturing for 24 hours, followed by filtration and sterilization to obtain the fermentation broth.
[0135] 2. Experimental Methods
[0136] The mice were adapted to the barrier environment for one week. In the 2nd to 9th week, the mice in the normal group and the model group were gavaged with 10 mL / kg sterile saline every day, and the mice in the control group were gavaged with 100 mg / kg metformin every day. The administration groups 1-3 and 5-6 were administered according to Table 13, respectively, and the probiotics in the bacteria group were gavaged with 10 mL / kg of saline and resuspended. The mice were fasted for 8 hours in advance every week, and blood (50 μl) was collected from the tail using a blood collection needle, and the blood glucose level was recorded. After the end of the 9th week, the mice were anesthetized and sacrificed, and their pancreatic islet tissues were observed by HE staining, and the mouse serum was collected to measure hemoglobin and insulin. The specific experimental operations are as follows:
[0137] (1) Mouse blood glucose detection
[0138] After the administration, the mice were fasted for 8 h, blood (50 μl) was collected from the tail using a blood collection needle, and the blood glucose level was measured using a blood glucose meter and recorded.
[0139] (2) HE staining of pancreatic islet tissue
[0140] Kidney and pancreatic tissues of mice were fixed in 4% paraformaldehyde for 24 hours, and then dehydrated by gradient ethanol (30%-100%), xylene clearing and wax immersion, paraffin embedded, tissue sectioned, and stained with hematoxylin-eosin (H&E). The staining results were observed under a microscope.
[0141] (3) Hemoglobin and insulin determination
[0142] After the mice were sacrificed, the mouse serum was collected and the glycated hemoglobin content was detected using a mouse glycated hemoglobin enzyme-linked immunosorbent assay kit (purchased from Nanjing Jiancheng Bioengineering Research Institute), and the insulin content was detected using a mouse insulin enzyme-linked immunosorbent assay kit (purchased from Nanjing Jiancheng Bioengineering Research Institute).
[0143] 2. Experimental results
[0144] After the administration, the fasting blood glucose changes, insulin levels, glycosylated hemoglobin detection and pancreatic islet tissue HE staining results of each group of mice are as follows:
[0145] (1) Mouse blood glucose test results
[0146] Figure 7 is the change of fasting blood glucose of mice in each group every week. Figure 7 It can be seen that the blood sugar levels of the drug groups 1 and 2 were significantly lower than those of the drug groups 4 and 5, indicating that both low-dose and high-dose Harbin Lactobacillus schreberi JNDM have a good blood sugar control effect on mice, and have long-term stability compared with the hypoglycemic drugs in the control group; at the same time, the hypoglycemic effect of drug group 3 is higher than that of drug group 6, indicating that the fermentation product of Harbin Lactobacillus schreberi JNDM also has a certain hypoglycemic effect. After the ninth week of the experiment, the results of the glycated hemoglobin test of each group of mice are as follows Figure 8 As shown, the results are consistent with the changes in blood sugar.
[0147] (2) Hemoglobin and insulin test results
[0148] Figure 8 The results of glycated hemoglobin testing of each group of mice after the ninth week of the experiment. Fig. 9 Insulin level and blood glucose protein level of mice, Figure 8 and Fig. 9 As shown, it can be seen that the insulin content in the medication groups 1 and 2 was significantly increased compared with those in the medication groups 4 and 5, and the glycated hemoglobin results were opposite to the trend of the insulin level, indicating that both low-dose and high-dose Harbin schfrei Lactobacillus JNDM have a good insulin production-promoting effect on mice and an inhibitory effect on glycated hemoglobin. At the same time, the hypoglycemic effect of the medication group 3 was higher than that of the medication group 6, indicating that the fermentation product of Harbin schfrei Lactobacillus JNDM also has a certain effect of promoting insulin production and inhibiting glycated hemoglobin.
[0149] (3) Results of HE staining of pancreatic islet tissue
[0150] like Fig.10 Islet tissue sections showed that the islet cells of normal mice were regular in shape and abundant in number, with no obvious abnormalities. The islet cells of diabetic mice all showed enlargement and reduction in number. Islet cell degeneration and loose and lightly stained cytoplasm appeared in drug-treated groups 4, 5, and 6. The number of islet cells in drug-treated groups 1 and 2 increased compared with drug-treated groups 4 and 5, and islet damage was repaired. At the same time, drug-treated group 3 also showed a significant improvement compared with drug-treated group 6. The experimental results show that the bacteria and its fermentation products have a certain promoting effect on the repair of islet cell damage.
[0151] Example 7 Drug Preparation
[0152] A process for preparing Harbin Lactobacillus JNDM powder comprises the following steps:
[0153] (1) Activation of bacterial strains: The strain was inoculated at a 3% inoculum into 100 mL of MRS medium under sterile conditions and cultured for 18 h.
[0154] (2) Seed solution preparation: The strain was inoculated at a 3% inoculum into 250 mL of MRS medium under sterile conditions and cultured for 16 h to obtain seed solution.
[0155] (3) Tank fermentation process: MRS medium was placed in a 5L fermenter at 80% liquid volume and sterilized at 115°C for 20 min. The fermentation temperature was set at 37°C, the rotation speed was 100 rpm / min, no ventilation, and the fermentation pH was controlled at 5.5 using 1 mol / L NaOH solution, and the fermentation was continued for 20 h.
[0156] (4) Bacterial cell collection: The fermentation broth was centrifuged at 4500 rpm / min for 8 min to collect the bacterial sludge.
[0157] (5) Freeze-drying protective agent formula: Add 10% skim milk powder, 5% lactose, and 5% sodium glutamate according to weight ratio and mix well.
[0158] Among them, freeze-dried bacterial powder: the bacterial mud and protective agent were mixed in a ratio of 1:1, freeze-dried in a freeze dryer, pre-frozen at -40°C for 4 hours, and sublimated at 30°C for 24 hours to obtain freeze-dried bacterial powder. The number of viable bacteria in the freeze-dried bacterial powder was 5×10 11 CFU / g.
[0159] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the solution. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents based on the understanding of the present solution without departing from the purpose and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.
Claims
1. A strain of Schleiferilactobacillus harbinensis JNDM, characterized in that: The Harbin Lactobacillus Schleifer JNDM was deposited in the Guangdong Provincial Microbiological Culture Collection Center on December 11, 2023, with the collection number: GDMCC No.64143.
2. Use of the Harbin Lactobacillus Schleifer JNDM according to claim 1 in the preparation of medicines or functional products for preventing, treating or assisting in the treatment of type 2 diabetes or its complications.
3. Application of Harbin Lactobacillus Schleifer JNDM according to claim 1 in the preparation of hypoglycemic drugs or hypoglycemic functional products.
4. The use according to claim 3, characterized in that: The Harbin Lactobacillus Schleifer JNDM achieves blood sugar reduction by promoting the proliferation of pancreatic islet cells and the secretion of insulin.
5. A blood sugar lowering drug, characterized in that: It comprises the Harbin Lactobacillus Schleifer JNDM and / or its bacterial liquid as described in claim 1.
6. The hypoglycemic drug according to claim 5, characterized in that: It also includes pharmaceutical excipients or carriers.
7. The hypoglycemic drug according to claim 5, characterized in that: The medicine is in the form of tablets, capsules, lyophilized powder or oral preparation.
8. A product with hypoglycemic function, characterized in that: It comprises the Harbin Lactobacillus Schleifer JNDM described in claim 1.
9. A blood sugar lowering bacterial powder, characterized in that: Contains the Harbin Lactobacillus Schleifer JNDM and / or its metabolites as described in claim 1.
10. The blood sugar lowering bacterial powder according to claim 9, characterized in that: The viable bacteria count of Harbin Lactobacillus Schleifer JNDM in the hypoglycemic bacteria powder is 5×10 8 -1×10 12 CFU / g.
Citation Information
Patent Citations
Application of lactobacillus probiotics CGMCC No.1. 13855 in preparation of diabetes treatment drugs
CN114533768A
Bifidobacterium bifidum for treating diabetes and related conditions
CN115948273A
Lactobacillus plantarum 84-3 with hypoglycemic and lipid-lowering functions and application thereof
CN114621896A
Harbin Lactobacillus stulafferi Z171 strain and application of exopolysaccharide thereof in preparation of blood fat reducing preparation
CN117025480A
Lactobacillus Harbin and application thereof in fermentation of sour porridge
CN117603860A
